Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 7—July 2005
Synopsis

SARS Vaccine Development

Shibo Jiang*Comments to Author , Yuxian He*, and Shuwen Liu*
Author affiliations: *New York Blood Center, New York, New York, USA

Main Article

Figure 1

Strategy for designing vaccines for severe acute respiratory syndrome (SARS) using inactivated SARS-associated coronavirus. This virus expresses several structural proteins, including nucleocapsid (N), membrane (M), envelope (E), and spike (S).

Figure 1. . Strategy for designing vaccines for severe acute respiratory syndrome (SARS) using inactivated SARS-associated coronavirus. This virus expresses several structural proteins, including nucleocapsid (N), membrane (M), envelope (E), and spike (S).

Main Article

Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external